View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsYooma Wellness 将来の成長Future 基準チェック /06現在、 Yooma Wellnessの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Personal Products 収益成長8.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).Board Change • May 26No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Sep 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Yooma Wellness は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:7AI - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202214-29-7-7N/A6/30/202214-31-8-8N/A3/31/202213-33-8-8N/A12/31/202110-33-11-11N/A9/30/20215-9-8-8N/A6/30/20213-7-6-6N/A3/31/20211-5-5-5N/A12/31/20200-2-2-2N/Aアナリストによる今後の成長予測収入対貯蓄率: 7AIの予測収益成長が 貯蓄率 ( 0.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 7AIの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 7AIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 7AIの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 7AIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 7AIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHousehold 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/08/04 07:55終値2023/05/08 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Yooma Wellness Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 01Yooma Wellness May Be Subject to Delisting from or Other Remedies by One or Both of the ExchangesYooma Wellness Inc. (Company) announced that its wholly-owned subsidiary Yooma Europe Limited (“Yooma Europe”) has completed the sale of Birmingham-based Vitality CBD Limited (“Vitality”), a UK-focused CBD company, for a total consideration of $2.0 million (the “Disposal”) to Psilobrain Therapeutics Inc. (“Psilobrain”). The Company has faced and is continuing to face significant financial and operational challenges and liquidity constraints which have gradually increased in severity over the last year. With the completion of the Disposal, the Company no longer has any material operating business lines or revenue generating assets. While the Company is continuing to consider all available alternatives, as set out in greater detail in the Company’s press release dated February 9, 2023, there can be no assurance at this time that the Company will be successful in addressing its liquidity constraints on a timely basis or at all. If the Company is unable to secure additional sources of liquidity, it is anticipated that the Company will have no alternative other than to pursue a liquidation, winding-up or insolvency proceeding. As a consequence of the challenges and liquidity constraints faced by the Company, it has fallen out of compliance with its continuous disclosure obligations and with a number of the rules and policies of the Canadian Securities Exchange and the AQUIS Growth Market (the “Exchanges”). The Company has been subject to a cease-trade order issued by the Ontario Securities Commission since May 8, 2023, resulting from the Company’s inability to file its annual financial statements, management discussion and analysis and CEO and CFO certifications for the year ended December 31, 2022, and its common shares have also been suspended from trading on the Canadian Securities Exchange and the AQUIS Growth Market since that date. Based on the Company’s current financial condition and the anticipated proceeds of the Disposal, the Company no longer expects that it will be able to complete the steps necessary to lift the cease trade order on a timely basis or at all, and notes that it may be subject to delisting from or other remedies by one or both of the Exchanges.
Board Change • May 10No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Feb 10Yooma Announces an Exit from Japan and Wind-Down of OperationsYooma Wellness Inc. provided a corporate update. The Company is engaged in an ongoing operational restructuring aimed at addressing depressed market conditions in the CBD wellness industry, the Company's increasing liquidity constraints and lack of working capital. The initial phases of this restructuring involved the wind-down of the Company's operations in the United States last year, and has gradually expanded to include the Company's operations in other unprofitable markets. In parallel with these restructuring initiatives, the Company has also been engaged in a continuing review of strategic alternatives for the Company, however, that process has to date been unsuccessful in identifying a path forward.
Reported Earnings • Dec 01Third quarter 2022 earnings released: US$0.006 loss per share (vs US$0.034 loss in 3Q 2021)Third quarter 2022 results: US$0.006 loss per share (improved from US$0.034 loss in 3Q 2021). Revenue: US$2.42m (up 14% from 3Q 2021). Net loss: US$624.8k (loss narrowed 76% from 3Q 2021).
Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 31Second quarter 2022 earnings released: US$0.011 loss per share (vs US$0.042 loss in 2Q 2021)Second quarter 2022 results: US$0.011 loss per share (up from US$0.042 loss in 2Q 2021). Revenue: US$3.29m (up 51% from 2Q 2021). Net loss: US$1.13m (loss narrowed 65% from 2Q 2021).
Board Change • May 26No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Sep 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.